Tweet
Today I came across interesting news:
European marketing authorization application for Ikervis has been filed to the EMA for the treatment of Dry Eye Diseas
Full news here: http://www.santen.com/en/news/20131206.pdf
This Ikervis is a new name for Cyclokat (cyclokat was developing name). Cyclokat is a cyclosporine A but stronger (2x), and in interesting vehicle, making use nanotechnologies, which should help in penetrating to the right eye structures.
It should be better than Restasis, coz Restasis didn't receive green in Europe due to not being considered efficient. Hopefully it will be approved and we will be able to evaluate it.
European marketing authorization application for Ikervis has been filed to the EMA for the treatment of Dry Eye Diseas
Full news here: http://www.santen.com/en/news/20131206.pdf
This Ikervis is a new name for Cyclokat (cyclokat was developing name). Cyclokat is a cyclosporine A but stronger (2x), and in interesting vehicle, making use nanotechnologies, which should help in penetrating to the right eye structures.
It should be better than Restasis, coz Restasis didn't receive green in Europe due to not being considered efficient. Hopefully it will be approved and we will be able to evaluate it.